Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 601–700 of 1,003
Molecular glue degraders: exciting opportunities for novel drug discovery
Lemaitre, T., Cornu, M., Schwalen, F., Since, M., Kieffer, C., & Voisin-Chiret, A. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306845 · Cited by 36
“PPIs play crucial roles in cellular process, but a lot of them they are considered ‘undruggable’ targets for drug development due to their extended and not very specific interfaces [87].”
BackgroundSomsen, B. A., Cossar, P. J., Arkin, M. R., Brunsveld, L., & Ottmann, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400214 · Cited by 41
Self-citationDahan, I. M., & Pick, E. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1007-4 · Cited by 36
Modulation of Protein Dimerization by a Supramolecular Host–Guest System
Uhlenheuer, D. A., Wasserberg, D., Nguyen, H. D., Zhang, L., Blum, C., Subramaniam, V., & Brunsveld, L. (2009) · Chemistry - A European Journal · doi:10.1002/chem.200900462 · Cited by 36
Bisson, M. M. A., Kessenbrock, M., Müller, L., Hofmann, A., Schmitz, F., Cristescu, S. M., & Groth, G. (2016) · Scientific Reports · doi:10.1038/srep30634 · Cited by 36
“2b) corresponds to IC 50 values obtained for other protein-protein interaction inhibitors in previous studies 44 .”
Saturation scanning of ubiquitin variants reveals a common hot spot for binding to USP2 and USP21
Leung, I., Dekel, A., Shifman, J. M., & Sidhu, S. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524648113 · Cited by 39
Allosteric Modulators of Protein–Protein Interactions (PPIs)
Ni, D., Liu, N., & Sheng, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_13 · Cited by 38
Hendrikse, S. I. S., Contreras-Montoya, R., Ellis, A. V., Thordarson, P., & Steed, J. W. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00896j · Cited by 36
Thienoquinolines as Novel Disruptors of the PKCε/RACK2 Protein–Protein Interaction
Rechfeld, F., Gruber, P., Kirchmair, J., Boehler, M., Hauser, N., Hechenberger, G., Garczarczyk, D., Lapa, G. B., PREOBRAZHENSKAYA, M. N., Goekjian, P. G., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401605c · Cited by 36
High-Affinity Small Molecule Inhibitors of T Cell Costimulation: Compounds for Immunotherapy
Huxley, P., Sutton, D. H., Debnam, P. M., Matthews, I. R., Brewer, J. E., Rose, J., Trickett, M., Williams, D. D., Andersen, T. B., & Classon, B. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.09.011 · Cited by 36
The discovery of small molecule chemical probes of Bcl-XL and Mcl-1
Prakesch, M. A., Denisov, A. Y., Naïm, M., Gehring, K., & Arya, P. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.06.023 · Cited by 36
Targeting the Dimerization of Epidermal Growth Factor Receptors with Small‐Molecule Inhibitors
Yang, R., Yang, K. S., PIKE, L. J., & Marshall, G. R. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.00986.x · Cited by 36
“However, a number of recent successful examples [reviewed in (31)] have generated increased interest in this direction.”
BackgroundPrivileged scaffolds targeting reverse-turn and helix recognition
Che, Y., & Marshall, G. R. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.1.101 · Cited by 36
“Protein–protein interactions are central to many key biologic pathways and, thus, are attractive targets for drug discovery [1-6] .”
BackgroundNew Approaches to Difficult Drug Targets: The Phosphatase Story
Lazo, J. S., McQueeney, K. E., & Sharlow, E. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217721142 · Cited by 42
Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies
Kyle, H. F., Wickson, K. F., Stott, J., Burslem, G. M., Breeze, A. L., Tiede, C., Tomlinson, D. C., Warriner, S. L., Nelson, A. S., Wilson, A. J., et al. (2015) · Molecular BioSystems · doi:10.1039/c5mb00284b · Cited by 42
Vashisth, H., Storaska, A. J., Neubig, R. R., & Brooks, C. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400568g · Cited by 35
Yurlova, L., Derks, M., Buchfellner, A., Hickson, I., Janssen, M., Morrison, D., Stansfield, I., Brown, C. J., Ghadessy, F. J., Lane, D. P., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057113518067 · Cited by 36
Inhibition of 14-3-3/Tau by Hybrid Small-Molecule Peptides Operating via Two Different Binding Modes
Andrei, S. A., Meijer, F. A., Neves, J. F., Brunsveld, L., Landrieu, I., Ottmann, C., & Milroy, L. ‐. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00118 · Cited by 37
Directed Evolution Using Stabilized Bacterial Peptide Display
Navaratna, T. A., Atangcho, L., Mahajan, M. K., Vivekanandan, S., Case, M., Min, A., Tresnak, D. T., & Thurber, G. M. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10716 · Cited by 35
Solubility-Aware Protein Binding Peptide Design Using AlphaFold
Kosugi, T., & Ohue, M. (2022) · Biomedicines · doi:10.3390/biomedicines10071626 · Cited by 31
Protein–protein interactions of PDE4 family members — Functions, interactions and therapeutic value
Klußmann, E. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.10.005 · Cited by 37
“These “hot spots” can be targeted by small molecules [48, 49].”
BackgroundStructure–activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1
Bach, A., Stuhr‐Hansen, N., Thorsen, T. S., Bork, N., Moreira, I. S., Frydenvang, K., Padrah, S., Christensen, S. B., Madsen, K. L., Weinstein, H., et al. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00025f · Cited by 36
Gogate, P. N., Ethirajan, M., Kurenova, E., Magis, A. T., Pandey, R. K., & Cance, W. G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.041 · Cited by 39
Cysteine protease inhibition by nitrile-based inhibitors: a computational study
Quesne, M. G., Ward, R. A., & de Visser, S. P. (2013) · Frontiers in Chemistry · doi:10.3389/fchem.2013.00039 · Cited by 35
“Furthermore, research into finding suitable inhibitors of the cysteine protease family is paramount (Arkin and Wells, 2004; Rzychon et al., 2004; Drahl et al., 2005; Tyndall et al., 2005; Ehmke et al., 2011).”
BackgroundInfluentialSmall-molecule costimulatory blockade: organic dye inhibitors of the CD40–CD154 interaction
Margolles‐Clark, E., Umland, O., Kenyon, N. S., Ricordi, C., & Buchwald, P. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0519-3 · Cited by 35
“It is becoming increasingly clear that, at least in certain cases, small molecules can quite effectively inhibit PPIs despite the lack of well-defined binding pockets, such as those present on the traditional targets of most existing drugs (ion channels, enzymes, and G-protein coupled receptors), along the interacting…”
BackgroundArchitecture and hydration of the arginine‐binding site of neuropilin‐1
Mota, F., Fotinou, C., Rana, R. R., Chan, A. W. E., Yelland, T., Arooz, M. T., O'Leary, A. P., Hutton, J. A., Frankel, P., Zachary, I. C., et al. (2018) · FEBS Journal · doi:10.1111/febs.14405 · Cited by 37
Carro, L. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.267 · Cited by 40
Volkman, H. M., Rutledge, S. E., & Schepartz, A. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042761y · Cited by 39
Nutritional Proteomics: Methods and Concepts for Research in Nutritional Science
Schweigert�, F. J. (2007) · Annals of Nutrition and Metabolism · doi:10.1159/000102101 · Cited by 35
“Additionally, proteins may vary in function depending on whether or not they interact with other proteins [”
BackgroundBandyopadhyay, S., Ray, S., Mukhopadhyay, A., & Maulik, U. (2014) · Briefings in Bioinformatics · doi:10.1093/bib/bbu041 · Cited by 37
Romano, G. (2013) · ISRN Oncology · doi:10.1155/2013/305371 · Cited by 47
“Nevertheless, encouraging achievements were reported in designing small molecules that exhibited specific targeting for protein-protein interactions [181–184].”
BackgroundZhu, M.-R., Du, D., Hu, J., Li, L., Liu, J.-Q., Ding, H., Kong, X., Jiang, H., Chen, K., & Luo, C. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.59 · Cited by 36
Chae, H., Kwak, D., Lee, M., Chi, S., & Kim, K. B. (2018) · Nanoscale · doi:10.1039/c8nr06423g · Cited by 35
Özdemir, E. S., Halakou, F., Nussinov, R., Gürsoy, A., & Keskin, Ö. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_1 · Cited by 35
Wang, C.-C., & Chen, X. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00667 · Cited by 36
Kumar, M., Dhayabaran, V. V., Sudhapriya, N., Alagumuthu, M., Gideon, D. A., & Annapoorani, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104046 · Cited by 34
Kosugi, T., & Ohue, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010925 · Cited by 40
Andrews, M. D., Dack, K. N., de Groot, M. J., Lambert, M., Sennbro, C. J., Larsen, M., & Stahlhut, M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00422 · Cited by 38
The yeast two-hybrid system and its role in drug discovery
Lentze, N., & Auerbach, D. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.4.505 · Cited by 41
“The most commonly encountered argument is that protein interaction interfaces are inherently difficult to block using small molecules, due to the large number of relatively weak side chain contacts involved in the interaction and the lack of clear ‘landmarks’, such as clefts or cavities, in the interaction interface t…”
BackgroundCellular Cofactors of Lentiviral Integrase: From Target Validation to Drug Discovery
Taltynov, O., Desimmie, B. A., Demeulemeester, J., Christ, F., & Debyser, Z. (2012) · Molecular Biology International · doi:10.1155/2012/863405 · Cited by 37
“Therefore, obtaining validated starting points for chemical optimization of SMIPPIs has been difficult [11].”
BackgroundIn search of small molecules blocking interactions between HIV proteins and intracellularcofactors
Busschots, K., Rijck, J. D., Christ, F., & Debyser, Z. (2008) · Molecular BioSystems · doi:10.1039/b810306b · Cited by 39
Fu, J. W., Wu, Z., & Zhang, L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.005 · Cited by 34
The crystal structure of superoxide dismutase from Plasmodium falciparum
Boucher, I. W., Brzozowski, A. M., Brannigan, J. A., Schnick, C., Smith, D. J., Kyes, S., & Wilkinson, A. J. (2006) · BMC Structural Biology · doi:10.1186/1472-6807-6-20 · Cited by 41
Rea, V. E. A., Lavecchia, A., Giovanni, C. D., Rossi, F. W., Gorrasi, A., Pesapane, A., de Paulis, A., Ragno, P., & Montuori, N. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1249 · Cited by 33
“More recently, it was concluded that "hotspots" might be responsible for the high-affinity protein–protein interaction (52).”
BackgroundManoharan, P., & Ghoshal, N. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1337590 · Cited by 34
“…to compute free energies of binding (Guvench & MacKerell 2009).35 In reality, proteins can accommodate ligands by undergoing conformational changes (Arkin & Wells, 2004; Mobley, Chodera, & Dill, 2007), and water plays an important role in protein–ligand binding affinity (Hamelberg & McCammon,…”
BackgroundBalasubramanian, K., & Gupta, S. P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304152704 · Cited by 36
Wang, Y., Kim, J., & Hilty, C. (2020) · Chemical Science · doi:10.1039/d0sc00266f · Cited by 33
Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 39
Nevola, L., Martín‐Quirós, A., Eckelt, K., Camarero, N., Tosi, S., Llobet, A., Giralt, E., & Gorostiza, P. (2013) · Angewandte Chemie · doi:10.1002/ange.201303324 · Cited by 33
Application of natural product-inspired diversity-oriented synthesis to drug discovery
Marcaurelle, L. A., & Johannes, C. W. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8595-8_3 · Cited by 33
BAFF-targeting therapy, a promising strategy for treating autoimmune diseases
Sun, J. M., Zhou, L., Feng, J., Li, Y., & Shen, B. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.08.027 · Cited by 33
Poncet-Montange, G., Zhan, Y., Bardenhagen, J., Petrocchi, A., Leo, E., Shi, X., Lee, G. R., Leonard, P. G., Geck, M., Cardozo, M. G., et al. (2014) · Biochemical Journal · doi:10.1042/bj20140933 · Cited by 35
Singh, R., Sran, A. S., Carroll, D. C., Huang, J., Tsvetkov, L. M., Zhou, X., Sheung, J., McLaughlin, J., Issakani, S. D., Payan, D. G., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.067 · Cited by 33
Neutralizing endogenous chemokines with small molecules
Galzi, J., Hachet‐Haas, M., Bonnet, D., Daubeuf, F., Lecat, S., Hibert, M., Haiech, J., & Frossard, N. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.003 · Cited by 43
“…molecules, SP4206 and SP4160, illustrates that flexible regions of small protein ligands can be targeted by high affinity molecules binding at protein–protein interfaces that are poorly druggable, but can adjust their structure to accommodate the ligand (Arkin & Wells, 2004; Thanos et al., 2006).”
BackgroundInfluentialTargeted Inhibition of the NCOA1/STAT6 Protein–Protein Interaction
Lee, Y., Yoon, H., Hwang, S., Shin, M. K., Lee, J. H., Oh, M., Im, S., Song, J., & Lim, H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08972 · Cited by 35
Arnold, L. A., Estébanez‐Perpiñá, E., Togashi, M., Shelat, A. A., Ocasio, C. A., McReynolds, A. C., Nguyen, P. T., Baxter, J. D., Fletterick, R. J., Webb, P., et al. (2006) · Science s STKE · doi:10.1126/stke.3412006pl3 · Cited by 37
dicty B ase 2015: Expanding data and annotations in a new software environment
Basu, S., Fey, P., Jimenez‐Morales, D., Dodson, R. J., & Chisholm, R. L. (2015) · genesis · doi:10.1002/dvg.22867 · Cited by 36
“…modifications will be integrated into DictyMine. dictyPPI Protein–protein interactions (PPIs) are essential for most biological processes (Arkin and Wells, 2004). dic-tyBase curators annotate PPIs specific for Dictyostelium TOTAL DICTYBASE UPGRADE 2015 using the GO term “protein…”
BackgroundNorris, N. C., Bingham, R. J., Harris, G., Speakman, A., Jones, R., Leech, A., Turkenburg, J. P., & Potts, J. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276592 · Cited by 32
TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Song, Y., & Buchwald, P. (2015) · Current Drug Targets · doi:10.2174/1389450116666150223115628 · Cited by 34
Izumikawa, M., Hashimoto, J., Hirokawa, T., Sugimoto, S., Kato, T., Takagi, M., & Shin‐ya, K. (2010) · Journal of Natural Products · doi:10.1021/np900788e · Cited by 32
Evidence for in vivo interactions between dehydrins and the aquaporin AtPIP2B
Hernández-Sánchez, I. E., Maruri‐López, I., Balch, E. P. M., Becerra-Flora, A., Jaimes‐Miranda, F., & Jiménez-Bremont, J. F. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.095 · Cited by 32
Direct AKAP-mediated protein-protein interactions as potential drug targets.
Hundsrucker, C., & Klussmann, E. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-72843-6_20 · Cited by 35
“Several examples show that small molecule development for the disruption of protein–protein interactions is feasible (Arkin and Wells 2004).”
BackgroundGeneration and Characterization of a Chimeric Rabbit/Human Fab for Co-Crystallization of HIV-1 Rev
Stahl, S. J., Watts, N. R. M., Rader, C. M., DiMattia, M. A., Mage, R. G., Palmer, I. W., Kaufman, J. D., Grimes, J. M., Stuart, D. I., Steven, A. C., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.01.061 · Cited by 32
Template-induced macrocycle diversity through large ring-forming alkylations of tryptophan
Lawson, K. V., Rose, T. E., & Harran, P. G. (2013) · Tetrahedron · doi:10.1016/j.tet.2013.05.060 · Cited by 32
A Novel Enediynyl Peptide Inhibitor of Furin That Blocks Processing of proPDGF-A, B and proVEGF-C
Basak, A., Khatib, A., Mohottalage, D., Basak, S., Kolajova, M., Bag, S. S., & Basak, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007700 · Cited by 32
“Owing to increased stability, enhanced bioavailability, improved drug like property and easy accessibility by synthetic means, small molecule inhibitors are always preferred over proteins for therapeutic use [28].”
BackgroundPeptides derived from HIV‐1 Rev inhibit HIV‐1 integrase in a shiftide mechanism
Hayouka, Z., Rosenbluh, J., Levin, A., Maes, M., Loyter, A., & Friedler, A. (2008) · Biopolymers · doi:10.1002/bip.20930 · Cited by 32
Raffeiner, P., Röck, R., Schraffl, A., Hartl, M., Hart, J. R., Janda, K. D., Vogt, P. K., Stefan, E., & Bister, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2588 · Cited by 33
“PPIs are challenging targets for small-molecule inhibitors [14, 40], although there are examples of PPI inhibitors in the clinic [41-43].”
Targeting PTEN in Colorectal Cancers
Kotelevets, L., Scott, M. G. H., & Chastre, E. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_5 · Cited by 34
“One approach is to target certain domains within proteins that mediate these interactions (Berg 2003; Arkin et al. 2004) .”
BackgroundProtein–protein interactions in transcription: A fertile ground for helix mimetics
Guarracino, D. A., Bullock, B. N., & Arora, P. S. (2010) · Biopolymers · doi:10.1002/bip.21546 · Cited by 38
Zhang, Z., Song, T., Li, X., Wu, Z., Feng, Y., Xie, F., Liu, C., Qin, J., & Chen, H. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.10.050 · Cited by 31
Eri, R. D., Kodumudi, K. N., Summerlin, D. J., & Srinivasan, M. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20344 · Cited by 31
The Worst Drug Rule Revisited: Mathematical Modeling of Cyclic Cancer Treatments
Katouli, A. A., & Komarova, N. L. (2010) · Bulletin of Mathematical Biology · doi:10.1007/s11538-010-9539-y · Cited by 32
“Kinases are currently one of the most promising and most intensively pursued drug targets ( Arkin and Wells 2004 ), because of their high efficiency and low toxicity.”
BackgroundLee, L. K., Bryant, K. J., Bouveret, R., Lei, P.-W., Duff, A. P., Harrop, S. J., Huang, E. P., Harvey, R. P., Gelb, M. H., Gray, P. P., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.397893 · Cited by 31
“Furthermore, as the interface between two proteins is potentially much larger than can be covered by small molecules, an additional challenge is to target surfaces within these interfaces that will abrogate binding (45).”
BackgroundZhou, J., Lin, J., Zhou, C., Deng, X., & Xia, B. (2011) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmq128 · Cited by 31
Nanaware, P. P., Ramteke, M. P., Somavarapu, A. K., & Venkatraman, P. (2013) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24494 · Cited by 31
Review: nanoparticles in drug delivery for the treatment of cancer.
Arayne, M. S., & Sultana, N. (2006) · PubMed · Cited by 44
Therapeutic peptides for CNS indications: Progress and challenges
Morimoto, B. H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.011 · Cited by 32
“In each case, the peptides target proteinprotein interactions, which are particularly difficult interactions to disrupt with small molecules (Cossins and Lawson, 2015; Arkin and Wells, 2004).”
BackgroundSmall-Molecule Inhibitors of the CD40–CD40L Costimulatory Protein–Protein Interaction
Chen, J., Song, Y. G., Bojadzic, D., Tamayo, A., Landin, A. M., Blomberg, B. B., & Buchwald, P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01154 · Cited by 31
Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats
Arkin, M. R., Glicksman, M. A., Fu, H., Havel, J. J., & Du, Y. (2012) · Cited by 31
Self-citationEvaluation of “Credit Card” Libraries for Inhibition of HIV-1 gp41 Fusogenic Core Formation
Xu, Y. Y., Lü, H., Kennedy, J. P., Yan, X., McAllister, L. A., Yamamoto, N., Moss, J. A., Boldt, G. E., Jiang, S., & Janda, K. D. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc0600167 · Cited by 33
Inhibitor design by wrapping packing defects in HIV-1 proteins
Fernández, A., Rogale, K., Scott, R., & Scheraga, H. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404641101 · Cited by 31
Critical Role for a Single Leucine Residue in Leukemia Induction by E2A-PBX1
Bayly, R., Murase, T., Hyndman, B. D., Savage, R., Nurmohamed, S., Munro, K. A., Casselman, R., Smith, S. P., & LeBrun, D. P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02025-05 · Cited by 31
“Identifying small-molecule inhibitors of protein-protein interactions has proven challenging, in part because of the large interaction surfaces involved ( 2 ).”
BackgroundPresence and utility of intrinsically disordered regions in kinases
Kathiriya, J. J., Pathak, R. R., Clayman, E., Xue, B., Uversky, V. N., & Davé, V. (2014) · Molecular BioSystems · doi:10.1039/c4mb00224e · Cited by 30
Rand, A. W., Gonzalez, K. J., Reimann, C. E., Virgil, S. C., & Stoltz, B. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c13146 · Cited by 30
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma
Tsigelny, I. F., Mukthavaram, R., Kouznetsova, V. L., Chao, Y. S., Babić, I., Nurmemmedov, E., Pastorino, S., Jiang, P., Calligaris, D., Agar, N. Y. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5633 · Cited by 30
“The involved protein surfaces are wide open in terms of a solution and have a comparatively “flat” shape that is not amenable to selectivity of peptide or small molecule inhibitors [10].”
BackgroundConstruction of an IMiD-based azide library as a kit for PROTAC research
Liu, H., Sun, R., Ren, C., Qiu, X., Yang, X., & Jiang, B. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02120b · Cited by 30
Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction
Sun, H., Wang, J., Liu, S., Zhou, X., Dai, L. X., Chen, C., Xu, Q., Wen, X., Cheng, K., Sun, H., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00521 · Cited by 30
Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy
Cho, W., Won, S., Choi, Y., Yi, S., Park, J. B., Park, J., Kim, C. E., Narayana, C., Kim, J. H., Yim, J., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300978 · Cited by 33
Advanced Technologies for Studies on Protein Interactomes
Guan, H., & Kiss‐Toth, E. (2008) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2007_092 · Cited by 38
“In this system, three plasmids were co-transfected into the HeLa cells, including (1) the reporter firefly luciferase driven by an IL8 promoter (IL8-Luc), ( 2 ) an internal non-inducible control reporter Renilla luciferase reporter driven by the HSV Thymidine kinase promoter (pTKrLuc), and (3) a pool of cDNA expressio…”
MethodMAPPIT: A protein interaction toolbox built on insights in cytokine receptor signaling
Lievens, S., Peelman, F., Bosscher, K. D., Lemmens, I. H., & Tavernier, J. H. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.11.001 · Cited by 30
“Apparent flat interaction interfaces were shown to harbor binding hot spots and grooves that constitute targets for interference, and allosteric mechanisms of PPI disruption have been reported [49–51].”
BackgroundCasey, F., Pihan, É., & Shields, D. C. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900294x · Cited by 30
Breuer, S., Schievink, S. I., Schulte, A., Blankenfeldt, W., Fackler, O., & Geyer, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020033 · Cited by 31
“to a protein of interest [39,40].”
PinaColada: peptide–inhibitor ant colony ad-hoc design algorithm
Zaidman, D., & Wolfson, H. J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw133 · Cited by 31
Carney, D. W., Lukesh, J. C., Brody, D. M., Brütsch, M. M., & Boger, D. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611405113 · Cited by 29
Zanjirband, M., & Rahgozar, S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402120701 · Cited by 32
Mostashari, P., Marszałek, K., Aliyeva, A., & Khaneghah, A. M. (2023) · Molecules · doi:10.3390/molecules28062658 · Cited by 33
“It has been reported that the Arg89-Ala90 dipeptide on residues 65–130 of OVM is responsible for trypsin inhibitory activity [255].”
BackgroundGurung, A. B., Bhattacharjee, A., Ali, M. A., Al-Hemaid, F. M. A., & Lee, J. (2016) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2016.01.008 · Cited by 31
“These include the general lack of small-molecule starting points for drug design, the typical flatness of the interface, and the difficulty of distinguishing real from false binding, and the size and character of typical small-molecule libraries (Arkin and Wells, 2004).”
BackgroundGolovanov, A. P., Blankley, R. T., Avis, J. M., & Bermel, W. (2007) · Journal of the American Chemical Society · doi:10.1021/ja070505q · Cited by 29
Mapping the Binding Site of Thiopeptide Antibiotics by Proximity-Induced Covalent Capture
Baumann, S., Schoof, S., Harkal, S., & Arndt, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja710608w · Cited by 41
Character and evolution of protein–protein interfaces
Reš, I., & Lichtarge, O. (2005) · Physical Biology · doi:10.1088/1478-3975/2/2/s04 · Cited by 29
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.